Project Grant R01HL175335
Award Date 9/15/25
Completion Date 6/30/30
Dollars Obligated $694K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $402,911 Project Grant to The Trustees of Columbia University in the City of New York to develop a pericardial mRNA therapy for the treatment of myocardial infarction (heart attack). The research aims to create a new anti-inflammatory drug based on previous studies of stem cell derivatives for heart repair, which will be administered via minimally invasive...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $243,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund a 2-year project to engineer advanced RNA biodevices that leverage CRISPR and ADAR gene-editing technologies. The goal is to improve the efficiency and specificity of converting resident cardiac fibroblasts into functional cardiomyocytes, in order to boost...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $811,885 in funding to the J. David Gladstone Institutes in California to conduct research on epigenomic mechanisms of cardiac fibrosis and heart failure. The project aims to investigate the role of the MEOX1 gene as a key transcriptional regulator of fibroblast activation, fibrosis, and heart failure pathogenesis. The research leverages novel genetic mouse...
- The U.S. National Heart, Lung, and Blood Institute awarded a $803,768 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the J. David Gladstone Institutes, a non-profit biomedical research organization in California. The grant funding supports a research project titled "Chromatin Regulation of Immune Cells in Myocardial Inflammation", which aims to elucidate the role of the epigenetic regulator BRD4 in controlling monocyte differentiation and macrophage...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Albert Einstein College of Medicine provides $785,198 in funding to study the role of chaperone-mediated autophagy (CMA) in regulating cardiac fibroblast and myofibroblast function during heart repair following myocardial infarction. The research aims to investigate how CMA, a selective protein degradation process, modulates fibroblast phenotypic transitions and impacts...
- This $651,967 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to elucidate the role of cardiac tissue-resident macrophages in heart failure progression. The principal investigator at the Texas Heart Institute will conduct research over a 5-year period from August 2025 to May 2030 to determine how macrophage senescence contributes to cardiomyocyte dysfunction, inflammation, and impaired clearance of cellular debris in...
- The National Institutes of Health's National Heart, Lung, and Blood Institute awarded a $630,169 Project Grant on August 20, 2025 to Cedars-Sinai Medical Center for the federal Cardiovascular Diseases Research program (CFDA 93.837). The funding supports a research project titled "Nuclear Transport of Developmental Signaling Effectors" that aims to investigate the mechanism by which key signaling proteins (Smads) enter the cell nucleus to regulate gene transcription and embryonic...
- The University of California, Davis received a $400,417 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to conduct research on cardiac regenerative therapy using gene-edited stem cells. The goal is to improve transplantation outcomes and address the critical role of inflammation-induced cell death that impedes current cardiac stem cell therapies. The research aims to develop new treatments for end-stage heart failure, a...
- This federal Project Grant award of $740,037, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the regulation of angiogenesis (blood vessel formation) by cardiac fibroblasts following myocardial infarction. The key objectives are to investigate the temporal and spatial expression of pro- and anti-angiogenic factors secreted by cardiac fibroblasts to support cardiac repair and increase vascular...